Aug 31 (Reuters) - Cynapsus Therapeutics Inc CTH.TO
* Sunovion Pharmaceuticals to acquire Cynapsus Therapeutics
* Deal values Cynapsus at about US$624 million (or about CAN$820 million)
* Acquisition will be funded with cash on hand
* Cynapsus will receive US$40.50 per common share in cash
* Holders of co's warrants,stock options to get cash payment equal to difference between US$40.50,exercise price of such warrant or stock option
* BofA Merrill Lynch serves as financial advisor to Cynapsus
* Nomura Securities International, Inc. serves as exclusive financial advisor to Sunovion
* Sunovion would acquire Cynapsus' product candidate, APL-130277 Source text for Eikon: ID:nNRA2hx0me Further company coverage: CTH.TO